PMID- 16404937
OWN - NLM
STAT- MEDLINE
DCOM- 20060209
LR  - 20131121
IS  - 0023-2149 (Print)
IS  - 0023-2149 (Linking)
VI  - 83
IP  - 11
DP  - 2005
TI  - [Oral cavity manifestations of gastroesophageal reflux disease].
PG  - 33-8
AB  - The aim of the study was to investigate changes in the oral cavity and the 
      gastroesophageal zone of the patients receiving rabeprazol, a proton pump 
      inhibitor (PPI). The subjects were 88 patients with gastroesophageal reflux 
      disease (GERD), who had changes in the oral cavity typical of this disease. The 
      patients were divided into four groups. Group I included patients with 
      non-erosive reflux disease; the other three groups were formed according to the 
      degree of the severity of reflux esophagitis in accordance with Los Angeles 
      classification of GERD: A, B, and C. The patients were administered rabeprazol as 
      a PPI. The study found that oral cavity changes are associated with the degree of 
      the gastroesophageal reflux. The study demonstrated high efficacy of rabeprazol 
      in GERD patients with oral cavity changes.
FAU - Maev, I V
AU  - Maev IV
FAU - Barer, G M
AU  - Barer GM
FAU - Busarova, G A
AU  - Busarova GA
FAU - Pustovoit, E V
AU  - Pustovoit EV
FAU - Polikanova, E N
AU  - Polikanova EN
FAU - Burkov, S G
AU  - Burkov SG
FAU - Gurenev, G L
AU  - Gurenev GL
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Klin Med (Mosk)
JT  - Klinicheskaia meditsina
JID - 2985204R
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Benzimidazoles)
RN  - 0 (Enzyme Inhibitors)
RN  - 32828355LL (Rabeprazole)
RN  - EC 3.6.3.14 (Proton-Translocating ATPases)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Benzimidazoles/therapeutic use
MH  - Enzyme Inhibitors/therapeutic use
MH  - Esophagus/metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Gastroesophageal Reflux/*complications/drug therapy/metabolism
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Mouth/drug effects/metabolism/pathology
MH  - Omeprazole/analogs & derivatives/therapeutic use
MH  - Proton-Translocating ATPases/antagonists & inhibitors
MH  - Rabeprazole
MH  - Saliva/metabolism
MH  - Severity of Illness Index
MH  - Stomatitis/*etiology/pathology/prevention & control
MH  - Treatment Outcome
EDAT- 2006/01/13 09:00
MHDA- 2006/02/10 09:00
CRDT- 2006/01/13 09:00
PHST- 2006/01/13 09:00 [pubmed]
PHST- 2006/02/10 09:00 [medline]
PHST- 2006/01/13 09:00 [entrez]
PST - ppublish
SO  - Klin Med (Mosk). 2005;83(11):33-8.